Politics
After the failure of Question 4 in Massachusetts in 2024 there has been a resurgence of other more focused proposed legislation targeting reform of state laws regulating the use of psychedelics.
After an extensive history of psychedelic research in the 1960s and ’70s, scientists in the Czech Republic are now investigating a range of different psychedelics and their therapeutic applications supported by new legislation legalizing the medical use of psilocybin.
Thanks to organizing from local advocacy organizations, Minnesota has quietly become a hotbed of reform launching a psychedelic task force and deprioritized arrests related to entheogenic plants and fungi.
The future of ibogaine therapy was a central topic at the 2025 Psychedelic Science conference, where it was endorsed by former Texas governor Rick Perry and others. Other states are following suit, but some advocates worry about possible exploitation of the plant medicine.
In part 2 of our series on campaign finance, new complaints filed by former staffers of the Massachusetts Yes on 4 psychedelics initiative to the Massachusetts Office of Campaign and Political Finance appear to contradict assertions from a senior campaign advisor that payments were done in accordance with state law.
The state of Arizona has allocated $10 million in funding for ibogaine research as part of the 2026 fiscal year budget.
Two former campaign staffers of the failed Yes on 4 ballot initiative in Massachusetts have filed complaints with the state Office of Campaign and Political Finance alleging violations of campaign finance law.
Has the psilocybin therapy industry peaked already in Oregon? Growth is slow, and uncertainty reigns, but safeguards seem to be working.
The defeat of Question 4 in Massachusetts and the right wing mandate carried forward by voters increases uncertainty for policies that support access to psychedelics.
Massachusetts voters consider The Natural Psychedelic Substances Act which would legalize the possession and cultivation of certain psychedelics.
